| abstract |
A novel bone-pathobolism treating agent is provided.nA bone-pathobolism treating agent comprising at least onensubstance selected from the group consisting ofnosteoclastogenesis inhibitory factor (OCIF), its homologs, andnits variants and a polysaccharide or its derivatives. As thenpolysaccharide or its derivatives, heparin, dextran sulfatenand the like can be used. n A bone-pathobolism treating agent is provided which hasnexcellent therapeutic effect on bone-pathobolism such asnosteoporosis, hypercalcemia, or chronic articular rheumatismnand persistance of the activity. The agent is useful as anmedicine. |